• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

毛霉菌病:对2019冠状病毒病的一种新威胁,特别关注印度。

Mucormycosis: A new threat to Coronavirus disease 2019 with special emphasis on India.

作者信息

Ghosh Deganta, Dey Sagardeep, Chakraborty Himanko, Mukherjee Sneha, Halder Ankita, Sarkar Akash, Chakraborty Pallab, Ghosh Rajdeep, Sarkar Joy

机构信息

Department of Botany, Dinabandhu Andrews College, Garia, Kolkata, West Bengal, India, 700084.

Department of Botany, Acharya Prafulla Chandra College, New Barrakpur, Kolkata, West Bengal, India, 700131.

出版信息

Clin Epidemiol Glob Health. 2022 May-Jun;15:101013. doi: 10.1016/j.cegh.2022.101013. Epub 2022 Mar 19.

DOI:10.1016/j.cegh.2022.101013
PMID:35342843
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8934183/
Abstract

The main reason for the growth of mucormycosis in people with Coronavirus disease-2019 (COVID-19) is mainly produced by spp. The infective mechanisms and issues recognized in spp. are the cell wall, germination proteins, and enzymes assisted to iron sequestration, CotH protein, and positive regulation of the GRP78 cell receptor. Mucormycosis is mainly caused by the spp. such as , etc. that are gifted to numerous host defense mechanisms and attribute to the endothelium via specific receptors, GRP78 simplifying their endocytosis and angio-invasion. Factors such as hyperglycemia, elevated iron concentrations, and ketoacidosis have been shown to contribute to the pathogenesis in the tentative situation. The analytical data of 'black fungus disease' or 'mucormycosis', specify India reported for about 42.3% of published cases, followed by the USA about 16.9%, Iraq, Bangladesh, Iran, Paraguay, and 1 case each from Brazil, Mexico, Italy, UK, China, France, Uruguay, Turkey, and Austria. The COVID-19 infection is maybe a predisposing factor for mucormycosis and is related to a high mortality rate. Early recognition and restriction of hyperglycemia, liposomal amphotericin B, and surgical debridement are the bases in the successful managing of mucormycosis.

摘要

2019冠状病毒病(COVID-19)患者毛霉病增多的主要原因主要是由 属物种引起的。在 属物种中认识到的感染机制和问题包括细胞壁、萌发蛋白、协助铁螯合的酶、CotH蛋白以及GRP78细胞受体的正向调节。毛霉病主要由 属物种引起,如 等,这些物种具有多种宿主防御机制,并通过特定受体GRP78作用于内皮细胞,从而促进其胞吞作用和血管侵袭。高血糖、铁浓度升高和酮症酸中毒等因素已被证明在这种情况下会促进发病机制。“黑真菌病”或“毛霉病”的分析数据表明,印度报告的病例约占已发表病例的42.3%,其次是美国约16.9%,伊拉克、孟加拉国、伊朗、巴拉圭,以及巴西、墨西哥、意大利、英国、中国、法国、乌拉圭、土耳其和奥地利各有1例。COVID-19感染可能是毛霉病的一个易感因素,且与高死亡率相关。早期识别并控制高血糖、使用脂质体两性霉素B以及手术清创是成功治疗毛霉病的基础。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff48/8934183/95f79e9b7deb/gr7_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff48/8934183/855245b7e4ed/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff48/8934183/05ccefc058c2/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff48/8934183/bf9d6392e14f/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff48/8934183/c620e6c359fd/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff48/8934183/f779624c830c/gr5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff48/8934183/45714597e286/gr6_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff48/8934183/95f79e9b7deb/gr7_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff48/8934183/855245b7e4ed/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff48/8934183/05ccefc058c2/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff48/8934183/bf9d6392e14f/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff48/8934183/c620e6c359fd/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff48/8934183/f779624c830c/gr5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff48/8934183/45714597e286/gr6_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff48/8934183/95f79e9b7deb/gr7_lrg.jpg

相似文献

1
Mucormycosis: A new threat to Coronavirus disease 2019 with special emphasis on India.毛霉菌病:对2019冠状病毒病的一种新威胁,特别关注印度。
Clin Epidemiol Glob Health. 2022 May-Jun;15:101013. doi: 10.1016/j.cegh.2022.101013. Epub 2022 Mar 19.
2
Clinical and Mycologic Characteristics of Emerging Mucormycosis Agent Rhizopus homothallicus.新兴毛霉属种同源接合菌的临床和真菌学特征。
Emerg Infect Dis. 2023 Jul;29(7):1313-1322. doi: 10.3201/eid2907.221491.
3
Host-Pathogen Molecular Factors Contribute to the Pathogenesis of spp. in Diabetes Mellitus.宿主-病原体分子因素促成糖尿病中 spp. 的发病机制。
Curr Trop Med Rep. 2021;8(1):6-17. doi: 10.1007/s40475-020-00222-1. Epub 2021 Jan 22.
4
GRP78 and Integrins Play Different Roles in Host Cell Invasion during Mucormycosis.GRP78 和整合素在毛霉病宿主细胞侵袭中发挥不同作用。
mBio. 2020 Jun 2;11(3):e01087-20. doi: 10.1128/mBio.01087-20.
5
Bicarbonate correction of ketoacidosis alters host-pathogen interactions and alleviates mucormycosis.酮症酸中毒的碳酸氢盐纠正可改变宿主与病原体的相互作用并减轻毛霉菌病。
J Clin Invest. 2016 Jun 1;126(6):2280-94. doi: 10.1172/JCI82744. Epub 2016 May 9.
6
Epidemiology of Mucormycosis in India.印度毛霉菌病的流行病学
Microorganisms. 2021 Mar 4;9(3):523. doi: 10.3390/microorganisms9030523.
7
[Cutaneous mucormycosis caused by Rhizopus microsporus].由微小根霉引起的皮肤毛霉病
Ann Dermatol Venereol. 2014 Mar;141(3):201-5. doi: 10.1016/j.annder.2013.10.044. Epub 2013 Dec 11.
8
A prospective multicenter study on mucormycosis in India: Epidemiology, diagnosis, and treatment.印度毛霉菌病的前瞻性多中心研究:流行病学、诊断与治疗
Med Mycol. 2019 Jun 1;57(4):395-402. doi: 10.1093/mmy/myy060.
9
Surge of mucormycosis during the COVID-19 pandemic.新冠疫情期间毛霉菌病的爆发。
Travel Med Infect Dis. 2023 Mar-Apr;52:102557. doi: 10.1016/j.tmaid.2023.102557. Epub 2023 Feb 20.
10
CotH3 mediates fungal invasion of host cells during mucormycosis.CotH3 在毛霉病期间介导真菌入侵宿主细胞。
J Clin Invest. 2014 Jan;124(1):237-50. doi: 10.1172/JCI71349. Epub 2013 Dec 20.

引用本文的文献

1
Rare case of a chronic rhinocerebral mucormycosis.慢性鼻脑型毛霉菌病罕见病例。
Med Mycol Case Rep. 2024 Apr 9;44:100648. doi: 10.1016/j.mmcr.2024.100648. eCollection 2024 Jun.
2
COVID-19, Obesity, and GRP78: Unraveling the Pathological Link.新型冠状病毒肺炎、肥胖与葡萄糖调节蛋白78:揭示病理联系
J Obes Metab Syndr. 2023 Sep 30;32(3):183-196. doi: 10.7570/jomes23053.
3
COVID-19 associated Mucormycosis among ICU patients: risk factors, control, and challenges.重症监护病房患者中与 COVID-19 相关的毛霉菌病:危险因素、防控及挑战

本文引用的文献

1
A case report of COVID-19 associated pulmonary mucormycosis.1例新型冠状病毒肺炎相关肺毛霉菌病病例报告
Arch Clin Cases. 2021 Oct 27;7(3):46-51. doi: 10.22551/2020.28.0703.10172. eCollection 2020.
2
A comprehensive review of various categories of face masks resistant to Covid-19.对各类抗新冠病毒口罩的全面综述。
Clin Epidemiol Glob Health. 2021 Oct-Dec;12:100835. doi: 10.1016/j.cegh.2021.100835. Epub 2021 Aug 2.
3
Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India.COVID-19 相关毛霉菌病:全球及印度病例报告的系统综述。
AMB Express. 2023 Sep 22;13(1):99. doi: 10.1186/s13568-023-01599-8.
4
GRP78, a Novel Host Factor for SARS-CoV-2: The Emerging Roles in COVID-19 Related to Metabolic Risk Factors.GRP78,一种新型的新冠病毒宿主因子:其在与代谢风险因素相关的新冠肺炎中的新作用
Biomedicines. 2022 Aug 17;10(8):1995. doi: 10.3390/biomedicines10081995.
5
Polyene Antibiotics Physical Chemistry and Their Effect on Lipid Membranes; Impacting Biological Processes and Medical Applications.多烯抗生素的物理化学性质及其对脂质膜的影响;对生物过程和医学应用的影响
Membranes (Basel). 2022 Jun 30;12(7):681. doi: 10.3390/membranes12070681.
6
Current Treatment Options for COVID-19 Associated Mucormycosis: Present Status and Future Perspectives.2019冠状病毒病相关毛霉病的当前治疗选择:现状与未来展望
J Clin Med. 2022 Jun 23;11(13):3620. doi: 10.3390/jcm11133620.
7
Deferiprone: A Forty-Year-Old Multi-Targeting Drug with Possible Activity against COVID-19 and Diseases of Similar Symptomatology.地拉罗司:一种具有 40 年历史的多靶点药物,可能对 COVID-19 和具有相似症状的疾病具有活性。
Int J Mol Sci. 2022 Jun 16;23(12):6735. doi: 10.3390/ijms23126735.
Diabetes Metab Syndr. 2021 Jul-Aug;15(4):102146. doi: 10.1016/j.dsx.2021.05.019. Epub 2021 May 21.
4
High mortality co-infections of COVID-19 patients: mucormycosis and other fungal infections.新冠病毒肺炎患者的高死亡率合并感染:毛霉菌病和其他真菌感染。
Discoveries (Craiova). 2021 Mar 31;9(1):e126. doi: 10.15190/d.2021.5.
5
Rhinocerebral Mucormycosis and COVID-19 Pneumonia.鼻脑型毛霉菌病与新型冠状病毒肺炎
J Med Cases. 2021 Mar;12(3):85-89. doi: 10.14740/jmc3637. Epub 2021 Jan 19.
6
Sino-orbital mucormycosis in a COVID-19 patient: A case report.一名新冠肺炎患者的鼻窦眼眶毛霉菌病:病例报告
Int J Surg Case Rep. 2021 May;82:105957. doi: 10.1016/j.ijscr.2021.105957. Epub 2021 May 4.
7
When Uncontrolled Diabetes Mellitus and Severe COVID-19 Converge: The Perfect Storm for Mucormycosis.当未控制的糖尿病与重症 COVID-19 相遇:毛霉菌病的完美风暴。
J Fungi (Basel). 2021 Apr 15;7(4):298. doi: 10.3390/jof7040298.
8
COVID-19 triggering mucormycosis in a susceptible patient: a new phenomenon in the developing world?COVID-19 诱发易感患者发生毛霉菌病:发展中国家的一种新现象?
BMJ Case Rep. 2021 Apr 27;14(4):e241663. doi: 10.1136/bcr-2021-241663.
9
Title of the Article: Paranasal Mucormycosis in COVID-19 Patient.文章标题:新冠病毒感染患者的鼻旁窦毛霉病
Indian J Otolaryngol Head Neck Surg. 2022 Oct;74(Suppl 2):3407-3410. doi: 10.1007/s12070-021-02574-0. Epub 2021 Apr 22.
10
Mucormycosis after Coronavirus disease 2019 infection in a heart transplant recipient - Case report and review of literature.COVID-19 感染后心脏移植受者发生毛霉菌病 - 病例报告及文献复习。
J Mycol Med. 2021 Jun;31(2):101125. doi: 10.1016/j.mycmed.2021.101125. Epub 2021 Apr 2.